A simple and inexpensive haemozoin-based colorimetric method to evaluate anti-malarial drug activity
© Men et al.; licensee BioMed Central Ltd. 2012
Received: 8 May 2012
Accepted: 13 July 2012
Published: 9 August 2012
The spread of drug resistance in malaria parasites and the limited number of effective drugs for treatment indicates the need for new anti-malarial compounds. Current assays evaluating drugs against Plasmodium falciparum require expensive materials and equipment, thus limiting the search for new drugs, particularly in developing countries. This study describes an inexpensive procedure that is based on the advantage of a positive correlation between the haemozoin level of infected erythrocytes and parasite load.
The relationship between parasitaemia and the haemozoin level of infected erythrocytes was investigated after converting haemozoin into monomeric haem. The 50% inhibitory concentration (IC50) values of chloroquine, quinine, artemisinin, quinidine and clotrimazole against P. falciparum K1 and 9A strains were determined using the novel assay method.
The haemozoin of parasites was extracted and converted into monomeric haem, allowing the use of a colorimeter to efficiently and rapidly measure the growth of the parasites. There was a strong and direct linear relationship between the absorbance of haem converted from haemozoin and the percentage of the parasite (R2 = 0.9929). Furthermore, the IC50 values of drugs were within the range of the values previously reported.
The haemozoin-based colorimetric assay can be considered as an alternative, simple, robust, inexpensive and convenient method, making it applicable in developing countries.
KeywordsAnti-malarial Assay Haemozoin Malaria
Malaria is more than just a problem for tropical countries, it also is a major global public health concern. Annually, there are approximately 300 million new malaria infections and millions of deaths worldwide due to malaria [1, 2]. Because a vaccine for malaria is not available, chemotherapy is the main treatment. However, the rapid spread of resistance to current quinoline anti-malarials has made malaria a major global and important problem. In addition, artemisinin, from a Chinese herb (Qinghaosu) that has been used in the treatment of fevers for more than a thousand years, is now considered an essential component of artemisinin-based combination therapy against drug-resistant malaria [3, 4]. However, the malaria parasites have recently been found to be resistant to artemisinin [5–7]. The alarming spread of drug resistance and the limited number of effective drugs for treatment indicates how important it is to find new anti-malarial compounds.
For decades, the anti-malarial activity of a drug has been measured in vitro by quantifying the uptake of radioactive substrates by a parasite as a measure of growth and viability in the presence of the test drug [8, 9]. Although several in vitro methods exist, the 3H-hypoxanthine method  is a popular test for novel anti-malarial drugs, but it is labelled with radiation that presents a potential risk to safety, and it relies on relatively expensive radio-isotopes and includes multistep procedures that become increasingly problematic and impractical when the incidence of testing is increased. The other methods, including the PicoGreen [10, 11] and the SYBR Green I [12, 13] methods, are also considered to be expensive approaches regarding equipment and chemicals. In addition, there are other methods that are based on enzymatic reaction and/or antibodies that specifically detect the presence of histidine-rich protein II or parasite lactate dehydrogenase [14–16]. However, these methods involve multiple complex steps that are too expensive for developing countries, which makes them ill suited for screening potential anti-plasmodial drugs.
During the development and proliferation stage in host erythrocytes, the malaria parasites degrade haemoglobin for use as a major source of amino acids. This is accompanied by the release of free haem. With haem as a prosthetic group of haemoglobin, the iron is in the ferrous state, but free haem loses one electron and assumes the ferric state. This ferric haem could be oxidatively active and toxic to both the host cells and malaria parasites, and can even cause parasite death. Moreover, due to the absence of haem oxygenase, the parasite is unable to cleave haem into an open-chain free haem, which is necessary for cellular excretion . To protect itself, it is necessary for the parasite to convert haem to non-toxic metabolites. Principally, the parasite detoxifies free haem via neutralization with histidine-rich protein 2 [18, 19] and degradation with reduced glutathione [20, 21], but mostly with crystallization into haemozoin, which is a water-insoluble malarial pigment produced in the food vacuole [19, 22]. Therefore, a simple and inexpensive in vitro assay was developed based on the colorimetric quantification of haemozoin in infected red blood cells to evaluate the anti-malarial activity of drugs.
Chloroquine diphosphate, quinine sulphate, primaquine, clotrimazole, haemin chloride (haem), RPMI 1640 medium, hypoxanthine, and gentamycin were purchased from Sigma Aldrich Chemical Company (Tokyo, Japan). Albumax II (Gibco), and the other chemicals used in the present study were of a high grade. Plasmodium falciparum K1 (chloroquine resistant) and 3D7-9A (chloroquine susceptible) strains  were provided from Dr Osamu Kaneko and Dr Shusuke Nakazawa, respectively, from the Institute of Tropical Medicine, Nagasaki University, Japan.
Plasmodium falciparum K1 and 9A strains were maintained in vitro with continuous culture according to a previously described method with a slight modification . The culture medium consisted of RPMI 1640 supplemented with 0.025 mg/ml gentamicin, 0.01 mM hypoxanthine, 23.8 mM NaHCO3, 11 mM glucose and 0.5% albumax II, and adjusted to a pH of 7.3 to 7.4. The parasite was cultured and maintained in a tissue culture flask with complete culture medium containing 5% human erythrocytes. The parasite density was maintained at about 1.5% parasitaemia under an atmosphere of an AnaeroPack sachet (Mitsubishi Gas Chemical Company Inc, Tokyo, Japan) to create 20% CO2 and remove O2 (<0.1%) 37°C . Every two days, infected erythrocytes were transferred into fresh medium containing 5% human erythrocyte. The level of parasitaemia was determined by light microscopy on a Giemsa-stained thin blood smear, and parasitized erythrocytes were diluted when parasitaemia was higher than 5% in erythrocytes contained at 5% in culture medium, in order to lower parasitaemia and allow continuous growth. Parasite culture was diluted with fresh uninfected erythrocytes and culture medium to achieve a starting parasitaemia of 2% and a haematocrit of 5%. This final parasite culture was immediately used for anti-malarial assay.
The relationship between parasitaemia and haemozoin level
A culture of the P. falciparum K1 strain was serially diluted with uninfected erythrocytes in complete medium to yield a haematocrit of 5% and parasitaemia ranging from 0 to 10%. The serial culture containing 200 μl was prepared independently in triplicate in microtubes, followed by the addition of 800 μl of 2.5% sodium dodecyl sulphate in 0.1 M sodium bicarbonate pH 8.8, then the samples were mixed at room temperature for 15 min. After centrifugation at 13,000 rpm for 10 min, the supernatant was removed. The pellet was washed twice with 800 μl of 2.5% sodium dodecyl sulphate in 0.1 M sodium bicarbonate (pH 8.8), then 200 μl of 5% sodium dodecyl sulphate was added to 50 mM NaOH to convert the haemozoin into haem. After incubation at room temperature for 30 min, the sample (200 μl) was transferred to a 96-well microplate and scanned at 405/750 nm (A405 nm minus A750 nm) using an IMark microplate reader (Bio-Rad). After the background absorbance of haemozoin was purified of uninfected erythrocytes (5% haematocrit) then subtracted, the amount of haemozoin in the infected erythrocytes was presented as the absorbance at 405/750 nm and then plotted against parasitaemia.
Evaluating the anti-malarial activity of drugs using the haemozoin-based spectrophotometric method
where y is the absorbance at 405/750 nm; x is the logarithm of the drug concentration, min is the absorbance at 405/750 nm measured at time zero (starting point of assay), and max is the maximal absorbance of a particular drug. The Hill slope is the steepness of the curve. The logarithm of the concentration at zero was defined at 2 log lower than the lowest concentration of a particular drug.
Results and discussion
Relationship between the absorbance of the haem content of haemozoin and parasitaemia
Haemozoin-based colorimetric assay to determine the IC50 values
In vitro anti-malarial activities of drugs against chloroquine-susceptible (9A) and -resistant (K1) strains of Plasmodium falciparum
Mean IC50and 95% CI (μM)
P. falciparum K1 strain
P. falciparum 9A strain
0.258 (0.242 - 0.275)
0.398 (0.307 - 0.516)
0.873 (0.824 - 0.926)
0.132 (0.082 - 0.211)
0.805 (0.689 - 0.939)
1.67 (1.18 – 2.37)
23.03 (18.36 - 28.90)
0.139 (0.124 - 0.155)
0.483 (0.376 - 0.622)
In recent years, the number of laboratories, diagnosis centres and research institutes has risen in developing countries. However, most of them lack the modern equipment and expensive chemicals to apply new methods for screening anti-malarial candidates. In addition, some methods have potential risks of toxicity, so it is prudent to wear disposable gloves at all times when proceeding. Another obstacle is that many laboratories lack the facilities to treat toxic contamination before the toxin is discarded in the environment. The novel anti-malarial assay is safe, non-expensive and easy to apply in laboratories.
The standard curve obtained in this study was strongly linear between the absorbance of monomeric haem converted from haemozoin and the percentage of parasitaemia. The IC50 values of chloroquine and quinine obtained from the haemozoin-based colorimetric method are similar to other methods. Even though this report describes specific conditions, the current experiment has introduced an assay that is adaptable to a wide range of conditions. The results also show that using this method has several advantages over using current methods. First, the method is fast and is based on a simple technique that uses a microplate reader, which is available in most laboratories. Second, the assay is based on inexpensive chemicals with no requirement of cold storage. Last but not least, the assay of the inhibition of P. falciparum growth using a haemozoin-based colorimetric method is feasible, reproducible, non-toxic, and more convenient than other assays, which makes it particularly useful for developing countries in the screening of novel anti-plasmodials, as a useful high throughput screening method for anti-malarial drug candidates.
We gratefully acknowledge the Japan Student Services Organization (JASSO) that provided a scholarship for a short-time study in Japan (student exchange support programme) to Tran Thanh Men. This study was supported in part by the Global COE Program (2008 - 2012) and the Japan Initiative for Global Research Network on Infectious Diseases (J-GRID) for KH.
- Breman JG, Alilio MS, Mills A: Conquering the intolerable burden of malaria: what's new, what's needed: a summary. AmJTrop Med Hyg. 2004, 71: 1-15.Google Scholar
- Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR: Epidemiology of drug-resistant malaria. Lancet Infect Dis. 2002, 2: 209-218. 10.1016/S1473-3099(02)00239-6.View ArticlePubMedGoogle Scholar
- Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N: Artesunate combinations for treatment of malaria: meta-analysis. Lancet. 2004, 363: 9-17.View ArticlePubMedGoogle Scholar
- WHO: Guidelines for the treatment of malaria. 2006, World Health Organization, Geneva, SwitzerlandGoogle Scholar
- Muller O, Sie A, Meissner P, Schirmer RH, Kouyate B: Artemisinin resistance on the Thai-Cambodian border. Lancet. 2009, 374: 1419-View ArticlePubMedGoogle Scholar
- Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ: Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009, 361: 455-467. 10.1056/NEJMoa0808859.PubMed CentralView ArticlePubMedGoogle Scholar
- Noedl H, Se Y, Sriwichai S, Schaecher K, Teja-Isavadharm P, Smith B, Rutvisuttinunt W, Bethell D, Surasri S, Fukuda MM, Socheat D, Chan Thap L: Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis. 2010, 51: e82-e89. 10.1086/657120.View ArticlePubMedGoogle Scholar
- Desjardins RE, Canfield CJ, Haynes JD, Chulay JD: Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother. 1979, 16: 710-718. 10.1128/AAC.16.6.710.PubMed CentralView ArticlePubMedGoogle Scholar
- Elabbadi N, Ancelin ML, Vial HJ: Use of radioactive ethanolamine incorporation into phospholipids to assess in vitro antimalarial activity by the semiautomated microdilution technique. Antimicrob Agents Chemother. 1992, 36: 50-55. 10.1128/AAC.36.1.50.PubMed CentralView ArticlePubMedGoogle Scholar
- Corbett Y, Herrera L, Gonzalez J, Cubilla L, Capson TL, Coley PD, Kursar TA, Romero LI, Ortega-Barria E: A novel DNA-based microfluorimetric method to evaluate antimalarial drug activity. AmJTrop Med Hyg. 2004, 70: 119-124.Google Scholar
- Quashie NB, de Koning HP, Ranford-Cartwright LC: An improved and highly sensitive microfluorimetric method for assessing susceptibility of Plasmodium falciparum to antimalarial drugs in vitro. Malar J. 2006, 5: 95-10.1186/1475-2875-5-95.PubMed CentralView ArticlePubMedGoogle Scholar
- Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P, Riscoe M: Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother. 2004, 48: 1803-1806. 10.1128/AAC.48.5.1803-1806.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Vossen MG, Pferschy S, Chiba P, Noedl H: The SYBR Green I malaria drug sensitivity assay: performance in low parasitemia samples. AmJTrop Med Hyg. 2010, 82: 398-401.View ArticleGoogle Scholar
- Noedl H, Wernsdorfer WH, Miller RS, Wongsrichanalai C: Histidine-rich protein II: a novel approach to malaria drug sensitivity testing. Antimicrob Agents Chemother. 2002, 46: 1658-1664. 10.1128/AAC.46.6.1658-1664.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Makler MT, Ries JM, Williams JA, Bancroft JE, Piper RC, Gibbins BL, Hinrichs DJ: Parasite lactate dehydrogenase as an assay for Plasmodium falciparum drug sensitivity. AmJTrop Med Hyg. 1993, 48: 739-741.Google Scholar
- Druilhe P, Moreno A, Blanc C, Brasseur PH, Jacquier P: A colorimetric in vitro drug sensitivity assay for Plasmodium falciparum based on a highly sensitive double-site lactate dehydrogenase antigen-capture enzyme-linked immunosorbent assay. AmJTrop Med Hyg. 2001, 64: 233-241.Google Scholar
- Eckman JR, Modler S, Eaton JW, Berger E, Engel RR: Host heme catabolism in drug-sensitive and drug-resistant malaria. J Lab Clin Med. 1977, 90: 767-770.PubMedGoogle Scholar
- Huy NT, Serada S, Trang DT, Takano R, Kondo Y, Kanaori K, Tajima K, Hara S, Kamei K: Neutralization of toxic heme by Plasmodium falciparum histidine-rich protein 2. J Biochem. 2003, 133: 693-698. 10.1093/jb/mvg089.View ArticlePubMedGoogle Scholar
- Sullivan DJ, Gluzman IY, Goldberg DE: Plasmodium hemozoin formation mediated by histidine-rich proteins. Science. 1996, 271: 219-222. 10.1126/science.271.5246.219.View ArticlePubMedGoogle Scholar
- Atamna H, Ginsburg H: Heme degradation in the presence of glutathione. A proposed mechanism to account for the high levels of non-heme iron found in the membranes of hemoglobinopathic red blood cells. J Biol Chem. 1995, 270: 24876-24883. 10.1074/jbc.270.42.24876.View ArticlePubMedGoogle Scholar
- Huy NT, Kamei K, Yamamoto T, Kondo Y, Kanaori K, Takano R, Tajima K, Hara S: Clotrimazole binds to heme and enhances heme-dependent hemolysis: proposed antimalarial mechanism of clotrimazole. J Biol Chem. 2002, 277: 4152-4158. 10.1074/jbc.M107285200.View ArticlePubMedGoogle Scholar
- Francis SE, Sullivan DJ, Goldberg DE: Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. Annu Rev Microbiol. 1997, 51: 97-123. 10.1146/annurev.micro.51.1.97.View ArticlePubMedGoogle Scholar
- Maeno Y, Nakazawa S, le Dao D, Yamamoto N, Giang ND, Van Hanh T, le Thuan K, Taniguchi K: A dried blood sample on filter paper is suitable for detecting Plasmodium falciparum gametocytes by reverse transcription polymerase chain reaction. Acta Trop. 2008, 107: 121-127. 10.1016/j.actatropica.2008.05.001.View ArticlePubMedGoogle Scholar
- Trager W, Jensen JB: Human malaria parasites in continuous culture. Science. 1976, 193: 673-675. 10.1126/science.781840.View ArticlePubMedGoogle Scholar
- Takeuchi Y, Yamakawa N, Kaetsu M, Fujiwara K, Okada J: Experiences with AnaeroPack systems. J Jpn Assoc Anaerob Infect Res. 1992, 22: 106-112.Google Scholar
- Shuaibu MN, Wuyep PA, Yanagi T, Hirayama K, Tanaka T, Kouno I: The use of microfluorometric method for activity-guided isolation of antiplasmodial compound from plant extracts. Parasitol Res. 2008, 102: 1119-1127. 10.1007/s00436-008-0879-6.View ArticlePubMedGoogle Scholar
- Bhattacharya A, Mishra LC, Bhasin VK: In vitro activity of artemisinin in combination with clotrimazole or heat-treated amphotericin B against Plasmodium falciparum. AmJTrop Med Hyg. 2008, 78: 721-728.Google Scholar
- Karl S, Wong RP, St Pierre TG, Davis TM: A comparative study of a flow-cytometry-based assessment of in vitro Plasmodium falciparum drug sensitivity. Malar J. 2009, 8: 294-10.1186/1475-2875-8-294.PubMed CentralView ArticlePubMedGoogle Scholar
- Kurosawa Y, Dorn A, Kitsuji-Shirane M, Shimada H, Satoh T, Matile H, Hofheinz W, Masciadri R, Kansy M, Ridley RG: Hematin polymerization assay as a high-throughput screen for identification of new antimalarial pharmacophores. Antimicrob Agents Chemother. 2000, 44: 2638-2644. 10.1128/AAC.44.10.2638-2644.2000.PubMed CentralView ArticlePubMedGoogle Scholar
- Franke-Fayard B, Djokovic D, Dooren MW, Ramesar J, Waters AP, Falade MO, Kranendonk M, Martinelli A, Cravo P, Janse CJ: Simple and sensitive antimalarial drug screening in vitro and in vivo using transgenic luciferase expressing Plasmodium berghei parasites. Int J Parasitol. 2008, 38: 1651-1662. 10.1016/j.ijpara.2008.05.012.View ArticlePubMedGoogle Scholar
- Baniecki ML, Wirth DF, Clardy J: High-throughput Plasmodium falciparum growth assay for malaria drug discovery. Antimicrob Agents Chemother. 2007, 51: 716-723. 10.1128/AAC.01144-06.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.